-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, domestic listed pharmaceutical companies are intensively disclosing their performance forecasts for the first quarter of 2022, such as Xinlitai, Jiangzhong Pharmaceutical, Kelun Pharmaceutical, and Proton
.
Among them, the net profit of many companies is expected to be profitable, and the performance is very bright
.
For example, Xin Litai stated in its 2022 first-quarter performance forecast that the net profit attributable to shareholders of listed companies during the reporting period increased by 36.
45%–69.
44% year-on-year, or about RMB 211.
5767 million–RMB 262.
7271 million
.
The report shows that the net profit attributable to shareholders of listed companies in this quarter increased compared with the same period of the previous year, mainly due to the overall increase in sales revenue
.
Among them, the innovative drug Xinlitan, after a new round of negotiations to renew the National Medical Insurance Catalogue, has increased sales volume and has grown rapidly, and its sales are basically flat year-on-year; in addition, in 2021, the sales revenue of generic drugs that won the bid for national centralized procurement has also achieved good results.
growth
.
Proton expects to achieve a year-on-year increase of 150%-170% in operating income in the first quarter of 2022, about 1.
357 billion yuan to 1.
466 billion yuan; it is expected to achieve a year-on-year increase of 270%-290% in net profit attributable to shareholders of listed companies, about 3.
26 100 million yuan – 344 million yuan
.
As for the reasons for this change in performance, Proton shares said that it is mainly benefited from the continued high prosperity of the CDMO industry, and the continuous expansion and enrichment of the company's customer pipeline and product pipeline
.
It is understood that in the first quarter of 2022, Proton shares saw a strong growth in orders in hand, and the major orders received by the company in the early stage were successfully delivered during the reporting period.
–170%
.
Kelun Pharmaceutical expects that in the first quarter of 2022, the year-on-year growth rate of net profit attributable to the parent will rebound to 32%, 50%-70%, and the generic drug business will usher in a cash-out period
.
Kelun Pharmaceutical is an innovative pharmaceutical company whose main products cover the fields of anesthesia and analgesia, central nervous system, anti-infection, and parenteral nutrition
.
Zuoli Pharmaceutical recently released a pre-increase report for the first quarter of 2022, showing a year-on-year increase of 52.
98% to 62.
12%
.
From January to February, the company achieved a total operating income of about 156 million yuan, a year-on-year increase of about 70%
.
In addition, the pharmaceutical leader WuXi PharmaTech also released the company's main operating data from January to February 2022 on March 10.
The year-on-year growth rate of orders in hand and sales revenue both exceeded 65%, setting a record high
.
Additionally, it expects revenue to grow 65-68% year over year in the first quarter of 2022
.
Looking forward to the full year, the company's revenue growth is expected to reach 65-70% year-on-year
.
Of course, if there is an increase, there will be a decline.
The companies whose net profit is expected to lose in the first quarter of this year include Haichuang Pharmaceutical, Shouyao Holding, and Rongchang Biology
.
Among them, Rongchang Bio lost more serious losses.
The company expects to obtain a net profit of -445 million to -329 million in the first quarter of this year
.
However, from an overall perspective, analysts pointed out that pharmaceutical companies have entered a period of performance realization.
Under the background of the high prosperity of the industry, the performance of pharmaceutical companies in the first quarter of 2022 is generally expected to exceed expectations
.
And in the context of the accelerated development of the pharmaceutical industry, there is still a lot of room for growth in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, the net profit of many companies is expected to be profitable, and the performance is very bright
.
For example, Xin Litai stated in its 2022 first-quarter performance forecast that the net profit attributable to shareholders of listed companies during the reporting period increased by 36.
45%–69.
44% year-on-year, or about RMB 211.
5767 million–RMB 262.
7271 million
.
The report shows that the net profit attributable to shareholders of listed companies in this quarter increased compared with the same period of the previous year, mainly due to the overall increase in sales revenue
.
Among them, the innovative drug Xinlitan, after a new round of negotiations to renew the National Medical Insurance Catalogue, has increased sales volume and has grown rapidly, and its sales are basically flat year-on-year; in addition, in 2021, the sales revenue of generic drugs that won the bid for national centralized procurement has also achieved good results.
growth
.
Proton expects to achieve a year-on-year increase of 150%-170% in operating income in the first quarter of 2022, about 1.
357 billion yuan to 1.
466 billion yuan; it is expected to achieve a year-on-year increase of 270%-290% in net profit attributable to shareholders of listed companies, about 3.
26 100 million yuan – 344 million yuan
.
As for the reasons for this change in performance, Proton shares said that it is mainly benefited from the continued high prosperity of the CDMO industry, and the continuous expansion and enrichment of the company's customer pipeline and product pipeline
.
It is understood that in the first quarter of 2022, Proton shares saw a strong growth in orders in hand, and the major orders received by the company in the early stage were successfully delivered during the reporting period.
–170%
.
Kelun Pharmaceutical expects that in the first quarter of 2022, the year-on-year growth rate of net profit attributable to the parent will rebound to 32%, 50%-70%, and the generic drug business will usher in a cash-out period
.
Kelun Pharmaceutical is an innovative pharmaceutical company whose main products cover the fields of anesthesia and analgesia, central nervous system, anti-infection, and parenteral nutrition
.
Zuoli Pharmaceutical recently released a pre-increase report for the first quarter of 2022, showing a year-on-year increase of 52.
98% to 62.
12%
.
From January to February, the company achieved a total operating income of about 156 million yuan, a year-on-year increase of about 70%
.
In addition, the pharmaceutical leader WuXi PharmaTech also released the company's main operating data from January to February 2022 on March 10.
The year-on-year growth rate of orders in hand and sales revenue both exceeded 65%, setting a record high
.
Additionally, it expects revenue to grow 65-68% year over year in the first quarter of 2022
.
Looking forward to the full year, the company's revenue growth is expected to reach 65-70% year-on-year
.
Of course, if there is an increase, there will be a decline.
The companies whose net profit is expected to lose in the first quarter of this year include Haichuang Pharmaceutical, Shouyao Holding, and Rongchang Biology
.
Among them, Rongchang Bio lost more serious losses.
The company expects to obtain a net profit of -445 million to -329 million in the first quarter of this year
.
However, from an overall perspective, analysts pointed out that pharmaceutical companies have entered a period of performance realization.
Under the background of the high prosperity of the industry, the performance of pharmaceutical companies in the first quarter of 2022 is generally expected to exceed expectations
.
And in the context of the accelerated development of the pharmaceutical industry, there is still a lot of room for growth in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
